沃森生物13价肺炎结合疫苗获埃及上市许可

Core Viewpoint - Watson Bio's subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received marketing authorization for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Egyptian Drug Authority (EDA), marking a significant milestone for the company's international expansion [1]. Group 1: Product Details - The 13-valent pneumococcal polysaccharide conjugate vaccine is primarily intended for infants and children aged 6 weeks to under 5 years, aimed at preventing infections caused by 13 specific serotypes of pneumococcus [1]. - The vaccine includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, which are known to cause infectious diseases [1]. Group 2: Regulatory Milestones - The vaccine was initially approved for sale in China in 2020, and the recent approval in Egypt signifies the company's efforts to expand its market presence internationally [1].